The web and app versions of the interaction charts have been updated to include Genvoya®, a single tablet regimen containing elvitegravir, cobicistat, emtricitabine (FTC) and tenofovir alafenamide. Interactions are listed under the abbreviation E/C/F/TAF and the combination is currently classified as an integrase inhibitor.
We are preparing updated records for elvitegravir/cobicistat to reflect fully its administration as a single tablet regimen with emtricitabine and tenofovir-DF (Stribild®). Once this has been completed, the printable charts will be updated with these changes.
